| Name | Coronado Nursing Center |
|---|---|
| Location | 1751 N 15th St, Abilene, Texas |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 168 |
| Occupancy Rate | 57.98% |
| Medicare ID (CCN) | 675746 |
| Legal Business Name | Eastland Memorial Hospital District |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1649251026 |
| Organization Name | WINNIE-STOWELL HOSPITAL DISTRICT |
| Doing Business As | CORONADO NURSING CENTER |
| Address | 1751 N 15th St, Abilene, TX 79603 |
| Phone Number | 325-673-3531 |
News Archive
A new drug being studied for the treatment of muscle degenerating diseases has shown promising results. According to a study published today in the British Journal of Pharmacology, Debio 025 is as effective as current drugs but, crucially, does not cause unwanted immunosuppressive effects.
bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, today announced the successful completion of a $60 million Series D financing. In this round, new investors Deerfield Partners, RA Capital, Ramius Capital Group, and two undisclosed blue chip public investment funds joined existing investors ARCH Venture Partners, Third Rock Ventures, TVM Capital, and Forbion Capital Partners. In addition, Shire plc joined the round as a strategic investor.
The findings, released today by the AAA Foundation for Traffic Safety, indicate that 95 percent of those age 55 and older have one or more medical conditions, 78 percent take one or more medications, and only 28 percent have an awareness of the risks those medications might have on driving ability.
A research article published today in Science presents the first major analysis based on the Human Protein Atlas, including a detailed picture of the proteins that are linked to cancer, the number of proteins present in the bloodstream, and the targets for all approved drugs on the market.
› Verified 2 days ago
| NPI Number | 1649478975 |
| Address | 1751 N 15th St, Abilene, TX 79603 |
| Phone Number | 325-673-8892 |
News Archive
A new drug being studied for the treatment of muscle degenerating diseases has shown promising results. According to a study published today in the British Journal of Pharmacology, Debio 025 is as effective as current drugs but, crucially, does not cause unwanted immunosuppressive effects.
bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, today announced the successful completion of a $60 million Series D financing. In this round, new investors Deerfield Partners, RA Capital, Ramius Capital Group, and two undisclosed blue chip public investment funds joined existing investors ARCH Venture Partners, Third Rock Ventures, TVM Capital, and Forbion Capital Partners. In addition, Shire plc joined the round as a strategic investor.
The findings, released today by the AAA Foundation for Traffic Safety, indicate that 95 percent of those age 55 and older have one or more medical conditions, 78 percent take one or more medications, and only 28 percent have an awareness of the risks those medications might have on driving ability.
A research article published today in Science presents the first major analysis based on the Human Protein Atlas, including a detailed picture of the proteins that are linked to cancer, the number of proteins present in the bloodstream, and the targets for all approved drugs on the market.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A new drug being studied for the treatment of muscle degenerating diseases has shown promising results. According to a study published today in the British Journal of Pharmacology, Debio 025 is as effective as current drugs but, crucially, does not cause unwanted immunosuppressive effects.
bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, today announced the successful completion of a $60 million Series D financing. In this round, new investors Deerfield Partners, RA Capital, Ramius Capital Group, and two undisclosed blue chip public investment funds joined existing investors ARCH Venture Partners, Third Rock Ventures, TVM Capital, and Forbion Capital Partners. In addition, Shire plc joined the round as a strategic investor.
The findings, released today by the AAA Foundation for Traffic Safety, indicate that 95 percent of those age 55 and older have one or more medical conditions, 78 percent take one or more medications, and only 28 percent have an awareness of the risks those medications might have on driving ability.
A research article published today in Science presents the first major analysis based on the Human Protein Atlas, including a detailed picture of the proteins that are linked to cancer, the number of proteins present in the bloodstream, and the targets for all approved drugs on the market.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 2 |
| Total Amount of Fines in Dollars | $50441 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 22.09 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.61 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 70.69 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.12 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.5 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.86 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.72 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 11.55 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 98.53 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 3.7 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 20.24 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 19.01 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.33 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.74 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 68.74 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 86.22 | 82.93 |
News Archive
A new drug being studied for the treatment of muscle degenerating diseases has shown promising results. According to a study published today in the British Journal of Pharmacology, Debio 025 is as effective as current drugs but, crucially, does not cause unwanted immunosuppressive effects.
bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, today announced the successful completion of a $60 million Series D financing. In this round, new investors Deerfield Partners, RA Capital, Ramius Capital Group, and two undisclosed blue chip public investment funds joined existing investors ARCH Venture Partners, Third Rock Ventures, TVM Capital, and Forbion Capital Partners. In addition, Shire plc joined the round as a strategic investor.
The findings, released today by the AAA Foundation for Traffic Safety, indicate that 95 percent of those age 55 and older have one or more medical conditions, 78 percent take one or more medications, and only 28 percent have an awareness of the risks those medications might have on driving ability.
A research article published today in Science presents the first major analysis based on the Human Protein Atlas, including a detailed picture of the proteins that are linked to cancer, the number of proteins present in the bloodstream, and the targets for all approved drugs on the market.
› Verified 2 days ago
Northern Oaks Living & Rehabilitation Center Location: 2722 Old Anson Rd, Abilene, Texas 79603 Phone: (325) 676-1677 | |
The Oaks At Radford Hills Healthcare Center Location: 725 Medical Dr, Abilene, Texas 79601 Phone: (325) 672-3236 | |
Willow Springs Health & Rehabilitation Center Location: 4934 S 7th St, Abilene, Texas 79605 Phone: (325) 692-2172 | |
Mesa Springs Healthcare Center Location: 7171 Buffalo Gap Rd, Abilene, Texas 79606 Phone: (325) 692-8080 |